A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer

18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer.

To date, several radioactive tracers for imaging primary and recurrent prostate cancer are undergoing active investigation. In this case report fluorine-18 (F)eprostate-specific membrane antigen (PSMA)-1007 positron emission tomography (PET)/computed tomography imaging was performed, to our knowledge, for the first time in a patient with biochemical recurrence (prostate-specific antigen [PSA] 0...

VolitionRx Announces Study Results Showing NuQ ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test

NAMUR, Belgium, April 20, 2016 /PRNewswire/ -VolitionRx Limited (NYSE MKT: VNRX) today announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity. This is significantly higher than the most common blood test currently used to detect prostate cancer, the Prostate Specific Antigen (PSA), which is reported to detect 53% of prostate cancers a...

Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey

Objective(s): The aim of this study was to analyze detection rates and effectiveness of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program for prostate cancer in Japan, which is defined as a cancer-screening program for subjects without known cancer. It contains FDG-PET aimed at detection of cancer at an early stage with or without additional screening tests ...

PSMA PET in Prostate Cancer.

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.